Survodutide

No brand yet · Boehringer Ingelheim / Zealand. Strong liver-fat reduction, but roughly 1 in 4 people stopped treatment because of side effects, far above other drugs in this class.

Average weight loss

16.6%

Stopped for side effects

24.5%

Trial length

76 wk

Ranking score

n/r

SYNCHRONIZE-1 results

Phase 3 · 76 weeks · 3.6 mg or 6 mg weekly
Adults with obesity, no diabetes (n=725)

Weight loss

16.6%

Nausea

n/r

Vomiting

n/r

Diarrhea

n/r

Constipation

n/r

Quit due to side effects

24.5%

n/r = not reported. Placebo group: 3.2%.

Worth knowing

Discontinuation due to adverse events: about 24% (3.6 mg) and 25% (6 mg) vs 5.4% on placebo.
Liver fat fell by up to 63% in an imaging sub-study.

–

Not yet ranked

Side-effect data incomplete. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company: Boehringer Ingelheim / Zealand
Targets: GLP-1, Glucagon
Molecule: Peptide
Dosing: Injection, weekly
Status: Phase 3 complete

Compare with another drug

Sources

Fierce Biotech: SYNCHRONIZE-1 at ADA 2026

History

Jun 7, 2026
Survodutide SYNCHRONIZE-1 published: 16.6% weight loss, about 1 in 4 stopped for side effects.